Welcome to our dedicated page for NeuBase Therapeutics news (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on NeuBase Therapeutics stock.
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) is a biotechnology company pioneering a modular antisense technology platform aimed at addressing rare genetic diseases caused by mutant proteins. By leveraging a cohesive and highly precise approach, NeuBase's platform offers significant improvements over traditional gene silencing therapies. Combining the benefits of synthetic methodologies with the accuracy of antisense technologies, NeuBase is positioned to revolutionize treatments for genetic disorders.
The company's primary focus lies in tackling repeat expansion disorders, with initial programs targeting Huntington's disease and myotonic dystrophy, along with dominant genetic disorders. Their innovative platform aims to provide solutions for conditions that currently lack effective treatments.
In recent developments, NeuBase has garnered attention from the investment community. On September 6, 2023, Symetryx Corporation announced its acquisition of 20% of NeuBase's issued and outstanding common stock. Both companies are engaged in strategic discussions to optimize value for NeuBase's shareholders. With a reported cash balance of $14.7 million as of June 30, 2023, NeuBase is also considered an attractive candidate for potential mergers or acquisitions.
NeuBase is actively undergoing a strategic review to explore the best paths forward, including potential mergers, acquisitions, special dividends, or other means to maximize shareholder value. The largest shareholder, Symetryx, is committed to working closely with NeuBase to ensure judicious use of the company's assets during this process.
For more information, investors can contact Dan Ferry, Managing Director at LifeSci Advisors, LLC, at daniel@lifesciadvisors.com, or Todd Branning, Chief Financial Officer at NeuBase, at tbranning@neubasetherapeutics.com. Media inquiries can be directed to media@neubasetherapeutics.com.
NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference from November 16-18. The presentation is scheduled for November 17 at 8:40 a.m. ET. Attendees can join via the provided webcast link or on the company's website. NeuBase is focused on advancing genetic medicine through its proprietary PATrOL™ therapies to address genetic diseases at their source.
NeuBase Therapeutics CEO Dietrich Stephan will present at Tribe Public's webinar on October 28, 2020, at 8:30 a.m. PDT. His talk is titled "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes." Dr. Stephan is a pioneer in precision medicine, having co-founded NeuBase in 2018 and taken it public in 2019. He has extensive experience in the field, with a strong focus on addressing genetic diseases through innovative synthetic medicines. The event is complimentary but has limited capacity; registration is encouraged.
NeuBase Therapeutics (NASDAQ: NBSE) announced the appointment of Dr. Peter Nielsen, a pioneer in peptide nucleic acid (PNA) technology, to its scientific advisory board. Dr. Nielsen, renowned for his expertise in genetic medicine, will enhance NeuBase's capabilities in optimizing its PATrOL™ therapies. CEO Dietrich A. Stephan highlighted Dr. Nielsen's transformative contributions to genetics, expecting his insights to advance the company’s innovative synthetic medicines aimed at treating various genetic diseases. The collaboration signifies NeuBase's commitment to redefining therapeutic approaches.
NeuBase Therapeutics, led by CEO Dietrich Stephan, will present its advancements in gene silencing therapies at a webinar hosted by Tribe Public on August 26, 2020, at 8 AM PT. The 30-minute session will showcase NeuBase's PATrOL™ platform aimed at treating genetic diseases like Huntington's Disease and Myotonic Dystrophy. Attendees can register for this free event via Tribe Public's website.
Dr. Stephan, a leader in precision medicine, has a strong background in genetics and has significantly impacted biotechnology with multiple company foundations.
NeuBase Therapeutics (NBSE) reported strong pharmacokinetic and pharmacodynamic data validating its PATrOL™ platform for developing genetic therapies. The company successfully raised approximately $33.3 million to advance its Huntington’s Disease and Myotonic Dystrophy programs. As of June 30, 2020, it had $35.9 million in cash, a significant increase from $10.3 million in 2019. However, the company reported a net loss of $3.8 million for Q3 2020, compared to a loss of $2.0 million the previous year. Overall, NeuBase aims to enhance its pipeline addressing rare genetic diseases.
NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich Stephan will participate in the BTIG Virtual Biotechnology Conference 2020 on August 11 at 9:30 a.m. ET. This conference aims to highlight advancements in biotechnology, and NeuBase is at the forefront with its innovative PATrOL™ platform for developing antisense oligonucleotide therapies targeting genetic diseases. This session will be accessible via a webcast.
NeuBase Therapeutics (Nasdaq: NBSE) has appointed Dr. William Mann as the new Chief Operating Officer to enhance operational capabilities and advance strategic goals. Dr. Mann, with extensive experience in the biopharma sector, aims to optimize the infrastructure for accelerated growth utilizing NeuBase's PATrOL™ platform for gene silencing therapies. The leadership team is focused on addressing genetic diseases, with the expectation that Dr. Mann will bring valuable insights and drive the company's innovative approach to treatment.
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced its inclusion in the Russell 3000® and Russell Microcap® Indexes effective after the market opens on June 29, 2020. This membership reflects NeuBase's market capitalization and will enhance its visibility in the investment community. Membership in the Russell 3000® provides opportunities for automatic inclusion in the Russell 1000® or 2000® Indexes. The Russell indexes are benchmarks for $9 trillion in assets, widely used by institutional investors.
NeuBase Therapeutics, Inc. (NASDAQ: NBSE) announced participation in two significant virtual events. CEO Dietrich Stephan will engage in a fireside chat at the 6th Annual SunTrust Robinson Humphrey Life Sciences Summit on May 15 at 2:30 p.m. ET. Additionally, he will present a corporate overview at the RBC Capital Markets 2020 Global Healthcare Conference on May 20 at 1:20 p.m. ET. NeuBase focuses on innovative gene silencing therapies for rare genetic diseases, leveraging its proprietary PATrOL™ platform to enhance treatment options.
FAQ
What is the current stock price of NeuBase Therapeutics (NBSE)?
What is the market cap of NeuBase Therapeutics (NBSE)?
What does NeuBase Therapeutics, Inc. specialize in?
Which diseases is NeuBase currently targeting?
What recent developments have occurred at NeuBase?
What is the financial condition of NeuBase Therapeutics?
Who are the main points of contact for investors and media?
What strategic options is NeuBase exploring?
How does NeuBase’s platform improve upon existing treatments?
Why is NeuBase’s antisense technology considered groundbreaking?
How will the strategic review impact NeuBase’s future?
What role does Symetryx Corporation play in NeuBase’s future?
